HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development
HUB Organoids official news RSS · 行業原文收錄 · 來源發佈：Wed Jan 24 2024 17:36:01 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 07:03:32 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug discovery and development, today announced the global launch of its new IntegriGut Screen. This innovative screening service employs IBD patient-derived organoid monolayers (PDO Monolayers) allowing access to high-quality human data on epithelial barrier [
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。